We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer Ingelheim Cited for Misleading Aggrenox Promotion
Boehringer Ingelheim Cited for Misleading Aggrenox Promotion
April 1, 2005
Boehringer Ingelheim Pharmaceuticals has been cited by the FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) for running a journal advertisement containing unsubstantiated superiority claims about its stroke drug Aggrenox.